A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) - Catalog
A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
HLB00300404a
ACCESS
ACC
False
True
True
Coded
False
Epidemiology Study
Open BioLINCC Study
Adult
2009-10-01
2009-10-01
2008-10-01
2005-12-21
June 1995 - March 2003
DLD
Lung
non-HIV
non-COVID
11211
0
No
No
No
Yes
Yes
Yes
Biospecimen research is restricted to studies related to sarcoidosis. Use of data is unrestricted.
Lung Diseases
Sarcoidosis
To determine the etiology of sarcoidosis by establishing a case control, multi-center study. In addition to etiology, this study also sought to examine socioeconomic variables and the clinical course of patients with sarcoidosis, including quality of life.
Sarcoidosis is a chronic granulomatous disorder of unknown cause that is characterized by activation of T-lymphocytes and macrophages. For many years sarcoidosis was presumed to be an atypical manifestation of tuberculosis because of the similarity between the inflammatory responses of the two diseases. However, as culture techniques became more widely employed to diagnose tuberculosis and it became less common, it became clear that sarcoidosis was not simply a variation of tuberculosis. Data on the etiology of sarcoidosis have come from diverse sources: in clinical investigations, alveolitis has been found to precede granulomatous inflammation; in case control studies, familial aggregation has been identified; and in case reports, recurrence of granulomatous inflammation has been observed after lung transplantation. The cause may not prove to be a single, known exposure. Interactions of exposures with genetic dispositions could have important implications for our understanding of immune responses as well as the pathogenesis of sarcoidosis.
736 patients with sarcoidosis enrolled within 6 months of diagnosis from 10 clinical centers in the U.S. Using the ACCESS sarcoidosis assessment system, organ involvement was determined for the whole group and for subgroups differentiated by sex, race, and age (<40 or 40 and older). Cases were matched with a control, and there was a two-year follow-up on cases. The ACCESS group proposed an instrument fo defining organ involvement in sarcoidosis. Biological specimens included DNA, plasma, and bronchoalveolar lavage samples were obtained. The data set includes 718 cases, 686 controls, and two-year follow-up data on 241 cases.
The initial presentation of sarcoidosis is related to sex, race and age, and it tends to remain stable over two years in the majority of patients. The etiology is probably multifactoral with both genetic and environmental factors contributing.
Bronchial Lavage
DNA
Peripheral Blood Mononuclear Cells
Plasma
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
Cases: 718
Controls: 686
Last Modified: March 15, 2022, 10:56 a.m. -
Age
Control
Case
All
N
%
N
%
N
%
18-29
75
10.93
80
11.14
155
11.04
30-39
222
32.36
247
34.40
469
33.40
40-49
224
32.65
214
29.81
438
31.20
50-59
118
17.20
129
17.97
247
17.59
>=60
47
6.85
48
6.69
95
6.77
Last Modified: March 15, 2022, 10:56 a.m. -
Sex
Control
Case
All
N
%
N
%
N
%
Male
243
35.42
261
36.35
504
35.90
Female
443
64.58
457
63.65
900
64.10
Last Modified: March 15, 2022, 10:56 a.m. -
Race
Control
Case
All
N
%
N
%
N
%
White
380
55.39
393
54.74
773
55.06
Black
306
44.61
325
45.26
631
44.94
Last Modified: March 15, 2022, 10:56 a.m.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
-
Material Types
Last Modified: Nov. 30, 2015, 10:16 a.m. -
General Freeze/Thaw Status
-
Visits (Vials)
03/15/2022
Plasma DNA PBMC Bronchial Lavage Total 1 Visit per Subject 12,602 29,683 1,394 593 44,272
Last Modified: Dec. 16, 2022, 9:12 a.m. -
Visits (Subjects)
03/15/2022
Plasma Total number of subjects Average volume (ml) per subject 1 Visit per Subject 1,423 12.37 Bronchial Lavage Total number of subjects Average volume (ml) per subject 1 Visit per Subject 73 5.25 PBMC Total number of subjects Average vials per subject 1 Visit per Subject 1,218 1.14 DNA Total number of subjects Average mass (ug) per subject Average vials per subject 1 Visit per Subject 1,426 109.19 13.02
Last Modified: Dec. 16, 2022, 9:12 a.m.